Nantkwest / Immunitybio -> IBRX WKN: A2QQ2E ISIN: US45256X1037 Forum: Aktien User: captainpump97

Ja moin 😀

Also wenn man gerade darüber spricht. Gerade 16% plus xD

Also alle schön den Teller leer essen, dann wird der Kurs schon steigen! 😁

Ja, es bedarf nur noch der passenden Ergebnisse in finalen Studien, dann sollte der Vulkan ausbrechen. Aber genauso kann es bei Rückschlägen oder mangelhaften Ergebnissen weiter bergab gehen. Aber ich denke, man würde nicht so einen finanziellen Aufwand betreiben, wenn die Zwischenergebnisse nicht mehr als vielversprechend wären. Geht da irgendwas in die Hose, wäre nicht nur das Unternehmen finanziell stark geschädigt, sondern auch PSS selbst, vom Ansehen ganz zu schweigen.

Also, bei positiven News geht die Aktie ungebremst nach oben. 😏

"It's important to note it that the sell-off has occurred under low volume, which tells me that shareholders are not fleeing for the door. It also tells me, there shouldn't be an insurmountable amount of resistance that would stop a reversal or a potential spike in the share price following a press release. In fact, looking at the Daily chart (Figure 7), we can see that there is little to no volume above $20 per share."

"It has been roughly nine months since the establishment of ImmunityBio (IBRX) following the merger with its sister company, NantKwest. Since the merger, the company has made in advancing their late-stage clinical platforms in cancer and infectious diseases. In addition, the company has advanced their "Universal Boost" COVID T-cell vaccine into a Phase III study. What is more, the company has acquired several vaccine platforms comprising DNA to RNA to subunit proteins and has scaled their GMP capacity for vaccines and NK cells. Furthermore, ImmunityBio has advanced their trial enrollments in their pancreatic, breast, and bladder cancers. Moreover, the company received patents for their cancer vaccine and bladder cancer therapy to extend up to 2038. Additionally, the company is in a strong financial position following $300M in new debt financing from Dr. Patrick Soon-Shiong's NantCapital. Last but not least, the company expects to file their BLA for bladder cancer in Q1 of next year. ImmunityBio had a banner year in terms of strategic milestones that will set the company up for another strong year in 202. [2022] Unfortunately, the share price action has reacted inversely to the company's progress and is barely trading above its 52-week low. I expect 2022 to be a transformative year for ImmunityBio, and as a result, I remain bullish on IBRX for a long-term speculative investment."

Der Seeking Alpha Artikel ist sehr sehr positiv. 😊

notlikethis.gif

🥲

Na, alle schon angespitzt und erwartungsvoll? Weihnachtsgeld heut in den Topf werfen?

Diese Woche startet Phase 3 oder?

Ja bin total gespannt 👍🏻

Mal sehen was an der US Börse heute passiert.

Euch auch allen frohe Weihnachten meine Leidensgenossen! 🎅

Jo, wer dein geblieben ist hat bald ein breites Grinsen. Euch Allen frohe Weihnachten.